Table 2.
Association of PPARD and PPARG polymorphisms with glioma risk.
| Gene | SNP | Chr: position | HaploReg v4.1 | Group | Genotype | Allele frequency | Model | OR(95%CI) | P | FDR-P | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | AB | BB | MAF (A) | HWE- P | |||||||||
| PPARD | rs2016520 | 6: 35378778 | SiPhy cons, Promoter histone marks, Enhancer histone marks, DNAse, Motifs changed, GRASP QTL hits, Selected eQTL | case | 31 | 217 | 317 | 0.247 | Allele | 0.82(0.68–0.99) | 0.041 | 0.214 | |
| control | 37 | 217 | 255 | 0.286 | 0.385 | Co-dominant | 0.67(0.40–1.11) | 0.123 | 0.323 | ||||
| 0.80(0.62–1.03) | 0.085 | 0.275 | |||||||||||
| Dominant | 0.78(0.62–1.00) | 0.047 | 0.214 | ||||||||||
| Recessive | 0.74(0.45–1.21) | 0.231 | 0.404 | ||||||||||
| Additive | 0.81(0.67–0.99) | 0.037 | 0.214 | ||||||||||
| PPARD | rs67056409 | 6: 35383699 | Promoter histone marks, Enhancer histone marks, DNAse, Motifs changed, Selected eQTL | case | 32 | 226 | 310 | 0.255 | Allele | 0.82(0.68–1.00) | 0.046 | 0.214 | |
| control | 40 | 219 | 250 | 0.294 | 0.455 | Co-dominant | 0.64(0.39–1.06) | 0.081 | 0.275 | ||||
| 0.83(0.65–1.07) | 0.147 | 0.323 | |||||||||||
| Dominant | 0.80(0.63–1.02) | 0.072 | 0.275 | ||||||||||
| Recessive | 0.70(0.43–1.13) | 0.146 | 0.323 | ||||||||||
| Additive | 0.82(0.67–0.99) | 0.041 | 0.214 | ||||||||||
| PPARD | rs1053049 | 6: 35395618 | DNAse, Motifs changed, GRASP QTL hits, Selected eQTL | case | 30 | 203 | 334 | 0.232 | Allele | 0.78(0.64–0.95) | 0.012 | 0.214 | |
| control | 39 | 206 | 264 | 0.279 | 1.000 | Co-dominant | 0.60(0.37–1.00) | 0.051 | 0.214 | ||||
| 0.78(0.60–1.00) | 0.051 | 0.214 | |||||||||||
| Dominant | 0.75(0.59–0.96) | 0.020 | 0.214 | ||||||||||
| Recessive | 0.67(0.41–1.10) | 0.114 | 0.323 | ||||||||||
| Additive | 0.78(0.64–0.95) | 0.012 | 0.214 | ||||||||||
| PPARD | rs2206030 | 6: 35404354 | Enhancer histone marks, Motifs changed, NHGRI/EBI GWAS hits, Selected eQTL | case | 126 | 291 | 151 | 0.478 | Allele | 1.08(0.91–1.28) | 0.371 | 0.546 | |
| control | 106 | 255 | 148 | 0.459 | 0.929 | Co-dominant | 1.17(0.83–1.65) | 0.382 | 0.546 | ||||
| 1.12(0.84–1.48) | 0.436 | 0.573 | |||||||||||
| Dominant | 1.13(0.87–1.48) | 0.361 | 0.546 | ||||||||||
| Recessive | 1.08(0.81–1.45) | 0.587 | 0.685 | ||||||||||
| Additive | 1.08(0.91–1.29) | 0.365 | 0.546 | ||||||||||
| PPARG | rs2920503 | 3: 12324230 | Motifs changed | case | 55 | 233 | 280 | 0.302 | Allele | 1.00(0.83–1.20) | 0.985 | 0.986 | |
| control | 43 | 221 | 245 | 0.302 | 0.529 | Co-dominant | 1.12(0.72–1.73) | 0.612 | 0.695 | ||||
| 0.92(0.72–1.19) | 0.529 | 0.635 | |||||||||||
| Dominant | 0.95(0.75–1.21) | 0.702 | 0.776 | ||||||||||
| Recessive | 1.16(0.76–1.77) | 0.482 | 0.595 | ||||||||||
| Additive | 1.00(0.83–1.20) | 0.986 | 0.986 | ||||||||||
| PPARG | rs4073770 | 3: 12368233 | Enhancer histone marks, Motifs changed, Selected eQTL | case | 60 | 265 | 243 | 0.339 | Allele | 0.99(0.83–1.19) | 0.924 | 0.972 | |
| control | 69 | 209 | 231 | 0.341 | 0.061 | Co-dominant | 0.83(0.56–1.22) | 0.339 | 0.546 | ||||
| 1.21(0.93–1.56) | 0.152 | 0.323 | |||||||||||
| Dominant | 1.11(0.87–1.41) | 0.390 | 0.546 | ||||||||||
| Recessive | 0.75(0.52–1.09) | 0.132 | 0.323 | ||||||||||
| Additive | 0.99(0.83–1.18) | 0.925 | 0.971 | ||||||||||
| PPARG | rs1151988 | 3: 12511512 | Enhancer histone marks, Motifs changed, GRASP QTL hits, Selected eQTL | case | 7 | 133 | 428 | 0.129 | Allele | 0.84(0.66–1.07) | 0.162 | 0.324 | |
| control | 9 | 135 | 365 | 0.150 | 0.488 | Co-dominant | 0.66(0.24–1.80) | 0.418 | 0.566 | ||||
| 0.84(0.64–1.11) | 0.217 | 0.396 | |||||||||||
| Dominant | 0.83(0.63–1.09) | 0.175 | 0.334 | ||||||||||
| Recessive | 0.69(0.26–1.87) | 0.470 | 0.595 | ||||||||||
| Additive | 0.83(0.65–1.07) | 0.154 | 0.323 | ||||||||||
SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; FDR, false discovery rate.
Bold values indicate statistical significance (P < 0.05).